

CURRICULUM VITAE

Name: Robert C. Knapp, MD.
Address: 20 Sutton Place South
New York, NY 10022-4165
Telephone: (212) 829-1209
Fax: (212) 753-9929
EMAIL robert_knapp_ma82@post.harvard.edu

Date of Birth: January 19, 1927
Place of Birth: New York, New York

Education:

1949 AB	Columbia College, New York, New York
1953 MD	College of Medicine of SUNY Downstate Medical Center
1982 MA (Hon)	Harvard University, Cambridge, Massachusetts
2003 DSc (Hon)	College of Medicine of SUNY Downstate Medical Center

(Hon)

Postdoctoral Training:

Internship and Residencies:

1953-1954	Intern, Kings County Hospital, Brooklyn, New York
1954-1957	Assistant Resident, Obstetrics and Gynecology, Kings County Hospital, Brooklyn, New York
1957- 1958	Chief Resident, Obstetrics and Gynecology, Kings County Hospital, Brooklyn, New York

Fellowships:

1962-1963	American Cancer Society Fellowship, College of Medicine of SUNY Downstate Medical Center
-----------	---

Licensure and Certification:

Certification

1954	National Board of Medical Examiners
1961	American Board of Obstetricians and Gynecologists
1974	Certification of Special Competence in Gynecologic Oncology

Licensure

1954	New York	075304 (active)
1957	Connecticut	08568 (active)
1969	California	G5339 (inactive)
1970	Massachusetts	32398 (inactive)

Academic Appointments:

1959-1962	Instructor in Obstetrics and Gynecology, Cornell University Medical College, New York, New York
1962-1963	Instructor in Gynecology, State University of New York Downstate Medical Center, Brooklyn, New York
1963-1969	Assistant Professor of Clinical Obstetrics and Gynecology, Cornell University Medical College, New York, New York
1969-1970	Associate Professor of Clinical Obstetrics and Gynecology, Cornell University Medical College New York, New York
1970-1975	Associate Professor of Obstetrics and Gynecology, Harvard Medical School, Boston, Massachusetts
1975-1993	William H. Baker Professor of Gynecology Harvard Medical School, Boston, Massachusetts
1993-	William H. Baker Professor of Gynecology, Emeritus Harvard Medical School, Boston, Massachusetts
2000-	Visiting Scholar in Obstetrics and Gynecology, Joan and Sanford I. Weill Medical College of Cornell University

Hospital Appointments:

1958-1966	Assistant Attending Obstetrician and Gynecologist, The New York Hospital, New York, New York
1966-1970	Associate Attending Obstetrician and Gynecologist, The New York Hospital, New York, New York
1967-1970	Chairman, Department of Obstetrics and Gynecology, Nassau County Medical Center, East Meadow, New York
1970-1975	Associate Chairman, Department of Obstetrics and Gynecology Beth Israel Hospital, Boston, Massachusetts
1970-1975	Head, Section on Gynecologic Oncology, Beth Israel Hospital, Boston, Massachusetts
1975-1980	Associate Chief of Staff and Director of Gynecology and Gynecologic Oncology, Boston Hospital for Women, Boston, Massachusetts
1975-1989	Chief, Division of Gynecologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
1980-1989	Director of Gynecology and Gynecologic Oncology, Brigham and Women's Hospital, Boston, Massachusetts
1980-	Consultant in Gynecology, Massachusetts General Hospital Boston, Massachusetts
1993-	Senior Gynecologist, Brigham & Women's Hospital, Boston Massachusetts
1975-1989	Director, Fellowship Program in Gynecologic Oncology, Brigham and Women's Hospital

Major Committee Assignments & Boards

National and Regional:

1973-1980	Board of Directors, American Cancer Society, Massachusetts
1983	Examiner American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology
1986-1987	Board of Directors, American Radium Society, Executive Committee
1997-	Board of Directors, Planned Parenthood of the Palm Beach and Treasure Coast Area
1998-	Board of Directors, Ovarian Cancer Research Fund

Hospital:

1975-1989	Chairman, Gyn Tumor Board, Brigham and Women's Hospital
1975-1989	Chairman, Gyn Cancer Committee, Brigham and Women's Hospital
1975-1989	Chairman, Gyn Care Committee, Brigham and Women's Hospital
1975-1987	Chairman, Gyn Complications Conference, Brigham and Women's Hospital
1975-1989	Executive Committee, Obstetrics and Gynecology Department
1975-1989	Credentials Committee, Obstetrics and Gynecology Department
1975-1986	Surgical Liaison Committee, Dana Farber Cancer Institute
1975-1987	Clinical Executive Committee, Dana Farber Cancer Institute
1979-1985	Chairman, Hospital Cancer Committee, Brigham and Women's Hospital
1985-1987	Chairman, Brigham and Women's Laser Committee
1986-1988	Chairman, Brigham and Women's Quality Assurance Committee; Obstetrics and Gynecology Department
1986-1988	Brigham and Women's Hospital Quality Assurance Committee

Editorial Boards:

1987-1990	Oncology and Biotechnology News, MED Pub Inc.
1988-1990	Journal Gynecologic Oncology

Memberships, Offices and Committee Assignments in Professional Societies

1960-	American College of Obstetricians and Gynecologists
1962-	American College of Surgeons

1966-	New York Cancer Society
1965-	New York Obstetrical Society
1966-	New York Gynecologic Society
1969-	American Society of Clinical Oncology
1971-	American Association for the Advancement of Science
1972-	Obstetrical Society of Boston
1972-	American Federation of Clinical Research
1973-	American Radium Society
1973-	American Society for Colposcopy and Colpomicroscopy
1975-	New England Cancer Society
1976-	Boston Surgical Society
1976-	Society of Gynecologic Oncologists
1979-	Society of Surgical Oncologists
1979-	American Association for Cancer Research
1979-	International Society of Gynecologic Pathologists
1980-	New England Association of Gynecologic Oncologists
1986-	International Gynecologic Oncology Society
1988-	Association of Professors of Gynecology and Obstetrics

Honors & Awards

1982	<i>Honorary Master Degree:</i>	Harvard University
1985	<i>Master Teachers Award:</i>	Alumni Assoc. of the College of Medicine of SUNY Downstate Medical Center
1996-	<i>The Annual Robert C. Knapp, M.D. Lectureship in Gynecology</i>	Brigham & Women's Hospital & Harvard Medical School
1997-	<i>The Annual Robert C Knapp, M.D. Lecture Series</i>	Established by Planned Parenthood of Palm Beach, Florida
2001-	<i>Margaret Sanger Award:</i>	Planned Parenthood of Palm Beach, Florida
2003	<i>Distinguished Alumni Achievement Award.</i>	Alumni Assoc. of the College of Medicine of SUNY Downstate Medical Center

Community Service Boards

1997- 2003	Planned Parenthood of Palm Beach, Florida
1998-2002	Ovarian Cancer Research Fund

Military Service

1944-46	United States Army
---------	--------------------

Author of 211 medical publications

Editor of textbook: *Gynecologic Oncology*

Co-inventor of the blood test for ovarian cancer: CA 125

Bibliography

1. Hall JE and Knapp RC: Mitral commissurotomy in pregnancy. Am J Obstet & Gynecol. 1956;72:970.
2. Knapp RC and Hellman LM: Acute renal failure in pregnancy. Am J Obstet & Gynecol. 1959;78:570.
3. Knapp RC, Platt MA and Douglas RG: Septic abortion: five year analysis at the New York Hospital. Obstet & Gynecol. 1960;15:344.
4. Landesman R and Knapp RC: Na²⁴ uterine muscle clearance in late pregnancy. Am J Obstet & Gynecol. 1960;80:92.
5. Knapp RC and Bonsnes RW: Delayed complications of hemorrhage. Clin Obstet & Gynecol. 1960;3:718.
6. Landesman R and Knapp RC: Diagnosis and treatment of toxemias of pregnancy: I.Diagnosis. NY State Med J. 1960;60:3830.
7. Landesman R and Knapp RC: Diagnosis and treatment of toxemias of pregnancy: II. Treatment. NY State Med J. 1960;60:4035.
8. Sweeney W and Knapp RC: Compound presentation: survey at the New York Hospital, 1932-1959. Obstet & Gynecol. 1961;17:333.
9. Landesman R, Halpern M and Knapp RC: Renal artery lesions associated with toxemias of pregnancy. Obstet & Gynecol. 1961;18:645.
10. Knapp RC and Warenski J: Clinical evaluation of dysfunctional labor. Obstet & Gynecol. 1963;21:627.
11. Ball TL, Knapp RC, Nathanson B and Lagasse L: Wedge resection of the bladder neck for failed operations in the surgery of stress urinary incontinence. Am J Obstet & Gynecol. 1966;94:997.
12. Knapp RC and Arditi L: Pregnancy complicated by the syndrome of patent ductus arteriosus with reversal of flow. NY State Med J. 1967;67:573.
13. Knapp RC and Arditi L: Closed mitral valvulotomy in pregnancy. Clin Obstet & Gynecol. 1968;2:978.
14. Knapp RC: The gynecological approach to ovarian tumors. Meadowbrook Staff J. 1968;1:164.

15. Knapp RC, Shapiro A and Reading PE: Maternal heart volume and prematurity. *Am J Obstet & Gynecol.* 1969;105:1252.
16. Knapp RC: Ovarian cancer. *Nassau Medical News* 1970;42:3.
17. Knapp RC. ed: Symposium on recent advances in pelvic malignancy. *Clin Obstet & Gynecol.* 1970;13:811.
18. Knapp RC and Feldman G: The problem of optimal management of cervical carcinoma in situ. *Clin Obstet & Gynecol.* 1970;13:889.
19. Knapp RC: Chemotherapy in ovarian carcinoma. *Trans N Engl Obstet & Gynecol Soc.* 1970;24:67.
20. Knapp RC and Polatsch B: Uterine procidentia complicated by incarceration. *NY State Med J.* 1971;71:672.
21. Friedman EA and Knapp RC: Forum: Has the survival rate from invasive carcinoma of the cervix been influenced by cytology screening? *Mod Med.* 1971;29:182.
22. Knapp RC, Cocotas S and Feldman GB: Treatment spectrum of intraepithelial carcinoma of the cervix. *Surg Gynecol & Obstet.* 1971;133:779.
23. Krumholz BA and Knapp RC: Colposcopic selection of biopsy sites. *Obstet & Gynecol.* 1972;39:22.
24. Knapp RC: Cervical cytology. *Consultant* 1972;12:172.
25. Knapp RC and Drucker DH: Self-inflicted stab wounds to pregnant uterus and fetus at term: Report of a case. *NY State Med J.* 1972;72:391.
26. Knapp RC and Donahue VC: Gynecologic surgery: Its threat to sexuality. *Consultant* 1972;12:55.
27. Feldman GB, Knapp RC, Order SE and Hellman S: The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. *Cancer Res.* 1972;32:1663.
28. Knapp RC and Drucker DH: Experiences with a young mother's clinic in a suburban county hospital. *NY State Med J.* 1973;73:332.
29. Knapp RC: Management of the suspicious posthysterectomy cytologic smear. *Int Corres Soc Obstet & Gynecol.* 1973;14:26.
30. Order S, Donahue VC and Knapp RC: Immunotherapy of ovarian carcinoma: An experimental model. *Cancer* 1973;32:573.

31. Knapp RC, Donahue VC and Friedman EA: Dissection of paravesical and pararectal spaces in pelvic operations. *Surg Gynecol & Obstet.* 1973;137:758.
32. Order SE, Kirkman R and Knapp RC: Serologic immunotherapy: Results and probable mechanism of action. *Cancer* 1974;34:175.
33. Order SE, Donahue VC and Knapp RC: Serologic immunotherapy and interaction with radiation. In: "Interaction of radiation and host immune defense mechanisms in malignancy", (Conference Proceedings, March 23-27, 1974 Greenbrier, West Va.) Brookhaven Nat Lab, Assoc Universities, Inc., 1974;363-378.
34. Burke L, Antonioli D, Knapp RC and Friedman EA: Vaginal adenosis: Correlation of colposcopic and pathologic findings. *Obstet & Gynecol.* 1974;44:257.
35. Feldman GB and Knapp RC: Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. *Am J Obstet & Gynecol.* 1974;119:991.
36. Knapp RC and Friedman EA: Aortic lymph node metastases in early ovarian cancer. *Am J Obstet & Gynecol.* 1974;119:1013.
37. Order SE, Thurston J and Knapp RC: Ovarian tumor antigens: A new potential for therapy. *Nat Cancer Instit Monograph.* 1975;42:33.
38. Knapp RC, Donahue VC and Friedman EA: Gynecologic cancer: Methods of office detection. *NY State Med J.* 1975;75:701.
39. Donahue VC and Knapp RC: Recent advances in the management of pelvic inflammatory disease. *Int Anesthesiol Clin.* 1976;14:149.
40. Donahue VC, DiSciullo AJ and Knapp RC: Gynecologic cancer detection and management. *Conn Med.* 1976;40:7.
41. Donahue VC, Knapp RC: Sexual rehabilitation of gynecologic cancer patients. *Obstet & Gynecol.* 1977;49:118.
42. Berkowitz RS and Knapp RC: Diagnosis and management of urinary stress incontinence. *Residnet & Staff Physician* 1977;23:100 (is).
43. Fuller AF, Schiff I and Knapp RC: Immunity, trophoblast and trophoblastic neoplasia. *Clin Obstet & Gynecol.* 1977;20:681.
44. Covell LM, DiSciullo AJ, and Knapp RC: Decidual changes in pelvic lymph nodes in the presence of cervical squamous cell carcinoma during pregnancy. *Am J Obstet & Gynecol.* 1977;127:674.
45. Burnstein S and Knapp RC: Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates. *J Med Chem.* 1977;20:950.

46. Knapp RC and Berkowitz RS: *Corynebacterium parvum* as an immunotherapeutic agent in an ovarian cancer model. *Am J Obstet & Gynecol.* 1977;128:782.
47. Berkowitz RX, Ehrmann RL and Knapp RC: Endometrial stromal sarcoma arising from vaginal endometriosis. *Obstet & Gynecol.* 1978;51:34 (s).
48. Knapp RC, Fuller AF and Schlossman SF: Immunology of gynecologic cancer. In: Caplan RM and Sweeney WJ III, eds. *Advances in obstetrics and gynecology.* Baltimore: The Williams & Wilkins Co., 1978;680.
49. Knapp RC and Berkowitz RS: Gynecologic cancer: Guide to diagnostic approach. *Hospital Medicine* 1978;14:3:88.
50. Knapp RC and Berkowitz RS: Diagnosis, staging and surgical therapy of endometrial cancer. *Surgical Rounds* 1978;1:8:22.
51. Knapp RC, Nelson JH, Leavitt T Jr., Levene MB, Parker LM, Easterday CL and Goldstein DP: Gynecologic Cancer. In: Cady B, ed. *Cancer: A manual for practitioners*, 5th ed. Boston: American Cancer Society Massachusetts Division, 1978;192.
52. Derbyshire C and Knapp RC: What to know about dysplasia, very early cancer and invasive cancer of the cervix. Communications Office, Sidney Farber Cancer Institute, Boston, MA, 1978.
53. Berkowitz RS, Leavitt T Jr and Knapp RC: Ultrasound directed percutaneous aspiration biopsy of periaortic lymph nodes in recurrence of cervical carcinoma. *Am J Obstet & Gynecol.* 1978;131:906.
54. Parker LM, Griffiths CT, Yankee RA, Knapp RC and Canellos GP: High dose methotrexate with leukovorin rescue in ovarian cancer: A phase II study. *Ca Treatment Reports* 1979;63:27.
55. Berkowitz RS and Knapp RC: The early detection of ovarian cancer. *The Female Patient* 1979;4:7:92.
56. Knapp RC and Berkowitz RS: Screening for carcinoma of the cervix. In: Hall DJ and Wood M, eds. *Cancer Screening, Cancer Control Program*, Communications Office of the Sidney Farber Cancer Institute, Boston: 1979;15.
57. Knapp RC, Odell LD and Richart RM: Put colposcopy to work for you? *Patient Care* 1979;13:14:124.
58. Cramer DW and Knapp RC: Review of epidemiologic studies of endometrial cancer and exogenous estrogen. *Obstet & Gynecol.* 1979;54:521.

59. Berkowitz RS, Ehrmann RL, Lavizzo-Mourey R and Knapp RC: Invasive cervical carcinoma in young women. *Gynecol Oncol.* 1979;8:311.
60. Bast RC Jr, Knapp RC, Mitchell A, Thurston J, Tucker R and Schlossman SF: Immunotherapy of a murine ovarian carcinoma with *Corynebacterium parvum* and specific heteroantiserum. *J Immunol.* 1979;123:1945.
61. Bruckman JE, Bloomer WD, Marck A, Ehrmann RL and Knapp RC: Stage III adenocarcinoma of the endometrium: Two prognostic groups. *Gynecol Oncol.* 1980;9:12.
62. Knapp RC and Berkowitz RS and Leavitt T Jr: Natural history and detection of ovarian cancer. In: Buchsbaum, H. ed. *Gynecology and Obstetrics, Volume IV--Oncology.* Hagerstown, Maryland: Harper and Row, 1980;1.
63. Derbyshire C and Knapp RC: What you need to know about dysplasia, very early cancer and invasive cancer of the cervix. Office of Cancer Communications, National Cancer Institute, Bethesda, Maryland, 1980.
64. Ehrmann RL, Federschneider JM and Knapp RC: Distinguishing lymph node metastases from benign glandular inclusions in low grade ovarian carcinoma. *Am J Obstet Gynecol.* 1980;136:737.
65. Bast RC Jr, Knapp RC, Donahue V, Thurston J, Mitchell A, Feeney M and Schlossman SF: Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. *J Nat Ca Inst.* 1980;64:365.
66. Mauch PM, Ehrmann RL, Griffiths CT, Marck A, Knapp RC and Levene MB: Radiation therapy in stage II ovarian carcinoma: The influence of histologic grade. *Cancer* 1980;45:1344.
67. Shaprio S, Kaufman DW, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Rosenshein NB, Watring WG, Leavitt T Jr, and Knapp RC: Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. *N Engl J Med.* 1980;303:485.
68. Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CR, Tobias JS, Weiner RS and Frei E: Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. *Cancer* 1980;46:669.
69. Shapiro S, Slone D, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt TL Jr, Watring WG, Rosenshein NB and Schottenfeld D: Use of thyroid supplements in relation to the risk of breast cancer. *JAMA* 1980;244:1685.

70. Kaufman SW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt TL Jr, Watring WG, Rosenshein NB, Lewis JL, Schottenfeld D and Engle R: Decreased risk of endometrial cancer among oral contraceptive users. *N Engl J Med.* 1980;18:1045.
71. Kinsella T, Bloomer WD, Lavin PT and Knapp RC: Stage II endometrial carcinoma: Ten year follow-up of combined radiation and surgical treatment. *Gynecologic Oncology* 1980;10:290.
72. Kaplan WD, Bloomer WD, Jones A, Federschneider JM and Knapp RC: Mediastinal lymphoscintigraphy in ovarian cancer using intraperitoneal autologous technetium-99m-labeled erythrocytes. *Brit J Radiol.* 1981;54:126.
73. Kaplan WD, Zimmerman RE, Bloomer WD, Knapp RC and Adelstein SJ: Therapeutic intraperitoneal 32p: A clinical assessment of the dynamics of distribution. *Radiol.* 1981;138:683.
74. Knapp RC and Federschneider JM: Hysterectomy: Abdominal. In: Schaefer G and Graber E, eds. *Complications in obstetric and gynecologic surgery.* Hagerstown, Maryland: Harper and Row, 1981;365.
75. Feeney M, Knapp RC, Greenberger JS and Bast RC Jr: Elimination of leukemic cells from rat bone marrow using antibody and complement. *Ca Res.* 1981;41:3331.
76. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB and Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. *J Clin Invest* 1981;68:1331.
77. Perez CA, Knapp RC and Young RC: Gynecologic Tumors. In: DeVita VT, Hellman S and Rosenberg SA, eds. *Principles and practices:* JB Lippincott Company, 1982;823.
78. Young RC, Knapp RC and Perez CA : Cancer of the ovary. In: DeVita VT, Hellman S and Rosenberg SA, eds. *Principles and practices:* JB Lippincott Company, 1982;884.
79. Green TH Jr and Knapp RC: Gynecology. In: Nardi GL and Zuidema GD, eds. *Surgery, essentials of clinical practice, 4th Ed.* Boston: Little Brown and Co; 1982:947.
80. Obrist R, Bast RC Jr, Berkowitz RS and Knapp RC: The immunology of gynecologic malignancies. In: Leventhal JM, ed. *Current Problems in Obstetrics and Gynecology.* Chicago: Year Book Medical Publishers; 1982: 5a:1.
81. Kearney GP and Knapp RC: Genitourinary complications of gynecologic cancers. In: Rieselback RE and Garnick MB, eds. *Cancer and the kidney.* Philadelphia: Lea and Febiger ;1982:742.

82. Knapp RC and Zucker PK: Vaginal cancer. In: Eiseman B, Robinson W and Steele G, eds. Follow-up care of the cancer patient. New York: Thieme-Stratton Inc. 1982:154.
83. Cramer DW, Hutchinson GB, Welch WR, Scully RE and Knapp RC: Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med. 1982;307:1047.
84. Powlis WD, Mauch P, Ehrmann RL, Rose CM, Knapp RC and Bloomer WD: The role of postoperative local or regional irradiation in the treatment of stage I ovarian cancer. Radiology 1982;142(3):747.
85. Obrist R, Reilly R, Leavitt T, Knapp RC and Bast RC Jr: Monocyte chemotaxis mediated by Formyl-Methionyl-Leucyl-Phenulalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmac. 1983;5:307.
86. Knapp RC: Today's look at gynecologic cancers. Patient Care 1983;17:123.
87. Knapp RC, Nelson JH Jr, Marchant DJ, Easterday CL, Leavitt T Jr, Parker L, Goldstein DP and Cramer D: Gynecologic cancer. In: Cady, B, ed. Cancer: A manuel for practitioners. 6th ED, Boston: American Cancer Society, 1983;212.
88. Bast RC Jr and Knapp RC: The immunobiology of ovarian carcinoma. In: Griffiths CT and Fuller AF Jr, eds. Gynecologic oncology. The Hague: Martinus Nijhoff 1983;187.
89. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Colvin RB: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell type. Am J Clin Path. 1983;79:98.
90. Knapp RC, St John E and Bast RC Jr: A review of intraperitoneal therapy of human ovarian carcinoma. Peritoneal Dialysis Bulletin, 1983;3:59.
91. Bast RC Jr and Knapp RC: Monoclonal antibodies reactive with human ovarian carcinoma. In: Wright GL Jr, ed. Monoclonal antibodies and cancer. New York: Marcel Dekker, 1983: 241.
92. Bast RC Jr, Berek JS, Orbist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD and Knapp RC: Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Cancer Res. 1983;43:1395.
93. Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R and Bast RC Jr: Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human ovarian carcinoma cell line. Am J Obstet & Gynecol. 1983: 146:607.

94. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zarawski VR and Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med.* 1983;309:883.
95. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC and Bhan AK: Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. *Int J Ca.* 1983;32:547.
96. Kawabat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC and Colvin RB: Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. *Int J Gynecol Path.* 1983;2:275.
97. Helmrich SP, Shapiro S, Rosenberg L, Kaufman DW, Slone D, Bain C, Miettinen OS, Stolley PD, Rosenshein NB, Knapp RC, Leavitt T Jr, Schottenfeld D, Engle RL and Levy M: Risk factors for breast cancer. *Am J Epidemiol.* 1983;117(1):35.
98. Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr: A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. *Cancer Res.* 1984;44:1048.
99. Knapp RC: Carcinoma of the vagina. In: Heintz APM, Griffiths CT and Trimbos JB, eds. *Surgery in gynecological oncology.* The Hague: Martinus Nijhoff, 1984;30.
100. Knapp RC: Surgical treatment of endometrial cancer. IN: Heintz APM, Griffiths CT and Trimbos JB, eds. *Surgery in gynecological oncology.* The Hague: Martinus Nijhoff, 1984;222.
101. Feig LA, Bast RC Jr, Knapp RC, Cooper GM: Somatic activation of ras K gene in a human ovarian carcinoma. *Science* 1984;223:698.
102. Bast RC Jr and Knapp RC: Immunologic monitoring techniques and immunotherapy. In: Bruckner HW and Cohen CJ ed. *Ovarian cancer: New approaches with curative intent.* Chicago: Sieber & McIntyre, Inc. 1984;73.
103. Bast RC Jr and Knapp RC: Immunologic approaches to the management of ovarian carcinoma. *Seminars in Oncol.* 1984;11:264.
104. Niloff JM, Klug TL, Schaetzel E, Zurawski VR Jr, Knapp RC, Bast RC Jr: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. *Am J Obstet & Gynec.* 1984;148:1057.
105. Masuho Y, Zalusky M, Knapp RC, Bast RC Jr: Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. *Cancer Res.* 1984;44:2813.

106. Bast RC Jr, Klug TL, Schaetzel E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Knapp RC: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9 and carcinoembryonic antigen. *Am J Obstet Gynecol.* 1984;149:553.
107. Niloff JM, Knapp RC, Schaetzel E, Reynolds C, Bast RC Jr: CA 125 antigen levels in obstetric and gynecologic patients. *Obstet Gynecol.* 1984;64:703.
108. Berek JS, Bast RC Jr, Lichtenstein A, Hacker NF, Spina CA, Lagaasse LD, Knapp RC, Zigelboim J: Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. *Obstet Gynecol.* 1984;64:708.
109. Lichtenstein A, Berek J, Bast RC Jr, Spina C, Hacker N, Knapp RC, Zigelboim J: Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with *Corynebacterium parvum*. *J Biol Resp Mod.* 1984;3:371.
110. Niloff JM, Bast RC Jr, Schaetzel EM and Knapp RC: Predictive value of CA 125 antigen at second-look procedures in ovarian cancer. *Am J Obstet Gynecol.* 1985;151:981.
111. Niloff JM, Knapp RC, Jones G, Schaetzel EM, Bast RC Jr: Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. *Cancer Treatment Reports.* 1985;69:895.
112. Lesko SM, Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Strom B, Schottenfeld D, Rosenshein NB, Knapp RC, Lewis J, Shapiro S: Cigarette smoking and the risk of endometrial cancer. *New Engl J Med.* 1985;313:593.
113. Knauf S, Anderson DJ, Knapp RC, Bast RC Jr: A study of the NB/70K and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. *Am J Obstet Gynecol.* 1985;152:911.
114. Bast RC Jr, Siegal FP, Schonholz D, Klug T, Zurawski V Jr, Cohen CJ, Knapp RC: Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. *Gynecol Oncol.* 1985;22:115.
115. Bast RC Jr and Knapp RC: Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. In: Alberts D and Surwit E eds. *Ovarian cancer.* The Hague: Martinus Nijhoff, 1985:23.
116. Perez CA, Knapp RC, DiSaia PJ, Young RC: Gynecologic tumors. In: DeVita VT, Hellman S and Rosenberg SA, eds. *Cancer, principles and practice of oncology: 2nd Edition,* Philadelphia: JB Lippincott Company, 1985;1013.
117. Young RC, Knapp RC, Fuks Z, DiSaia PJ: Cancer of the ovary. In: DeVita VT, Hellman S and Rosenberg SA, eds. *Cancer, principles and practice of oncology: 2nd Edition,* Philadelphia: JB Lippincott Company, 1985;1083.

118. Bast RC Jr and Knapp RC. Tumor markers: Monitoring epithelial ovarian cancer. *Laboratory Medicine*. 1985;16:315.
119. Bast RC Jr, Knapp RC: Use of the CA 125 antigen in diagnoses and monitoring of ovarian carcinoma. *Europ J Obstet Gynec Reprod Biol*. 1985;19: 354.
120. Knapp RC: Clinical application of a radioimmunoassay for ovarian cancer. In: *Current concepts in gynecological oncology*. Noordwijkerhout. The Netherlands, Boerhaave Committee for Postgraduate Medical Education. 1985;123-132.
121. Knapp RC: Ovarian cancer: Mode of spread and staging. In: *Current concepts in gynecological oncology*. Noordwijkerhout, The Netherlands, Boerhaave Committee for Postgraduate Medical Education 1985;139.
122. Bast RC, Jr, Klug T, Niloff JM, Knapp RC: The clinical usefulness of CA 125. *Cancer bulletin of the U of Texas M D Anderson Hospital and Tumor Institute of Houston*. 1985;37:80.
123. Bast RC Jr, Zurawski VR Jr, Knapp RC: Clinical application of monoclonal antibodies reactive with epithelial ovarian cancer. In : Reisfeld, RA and Fell, S, eds. *Roche UCLA Symposium. Monoclonal antibodies and cancer therapy*. New York, Alan R Liss, Inc. 1985;37-51.
124. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D: Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. *New Engl J Med*. 1985;313:969.
125. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighlboim J, Bast RC Jr: Intraperitoneal immunotherapy of epithelial ovarian carcinoma with corynebacterium parvum. *Am J Obstet & Gynecol*. 1985;152:1003.
126. Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzel E, Bast RC JR, Knapp RC, and Kufe DW: Circulating DF 3 and CA 125 antigen in serum from patients with epithelial ovarian cancer. *J Clin Oncol*. 1985;3:1355.
127. Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B and Zurawski VR Jr: Preoperative evaluation of serum CA 125 levels in patients with primary epithelial cancer. *Obstet Gynecol*. 1986;67:414.
128. Goodman H, Griffiths CT and Knapp RC: The Cervix. In: Kistner RW, ed. *Gynecology, principles and practice: 4th Edition*. Chicago: Year Book Medical Publishers Inc, 1986;97.

129. Bast RC Jr, Knapp RC: Concepts of gynecologic tumor immunology. In: Knapp RC and Berkowitz RS, eds. Gynecologic oncology. New York: Macmillan Co. 1986;97.
130. Niloff JM, Eifel PJ, Bloomer WD, Knapp RC: Malignancy of the uterine corpus, endometrial carcinoma. In: Knapp RC and Berkowitz R, eds. Gynecologic oncology. New York: Macmillan Co. 1986;275.
131. Bast RC Jr, Knapp RC: Antigenic markers for ovarian carcinoma. In: Rose NR, Frideman H and Fahey JL, eds. Manual of clinical immunology: 3rd Edition, Washington D C: Am Soc for Microbiology 1986;817.
132. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Hacker NF, Whitney C, Niloff JM, Bast RC Jr: CA 125 serum levels correlate with second-look operations among ovarian cancer patients: Obstet Gynecol. 1986;67:685.
133. Knapp RC: The gynecologic oncology unit. OB/Gyn perspectives 1986;49.
134. Knapp RC, Berkowitz RS, Curry SL, Fuller AF Jr, Goldstein DP, Griffiths CT, Madoc-Jones H, Parker L: Gynecologic cancer. In: Cady B, ed. Cancer: A manual for practioners, 7th ed. Boston, American Cancer Society, Massachusetts Division, 1986;222.
135. Bast RC Jr, Knapp RC: Monoclonal reagents in immunodiagnosis and immunotherapy of human epithelial ovarian carcinoma. In: Monoclonal antibodies for the diagnosis and therapy of cancer. Ed. JA Roth, Futura Publishing Co, New York 1986;61.
136. Barbieri RL, Niloff JM, Bast RC, Schaetzel E, Kistner RW, Knapp RC: Elevated serum concentrations of CA 125 in patients with advanced endometrosis. Fertil Steril. 1986;45:630.
137. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC Jr: The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986;155:56.
138. Niloff JM, Welch W, Taylor S, Battaile A, Anderson D, Knapp RC, Bast RC Jr: Antigenic heterogeneity in human ovarian carcinoma. Gynecol Oncol. 1986;23:246.
139. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC Jr: CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987;69:223.
140. Knapp RC, Forti DQ, Griffiths CT: A historical review of radical pelvic surgery. Surgical Rounds. 1987;10:91.

141. Kapnick SJ, Knapp RC: Malignancy in pregnancy. In: Pauerstein CJ, ed. Textbook of clinical obstetrics: New York, John Wiley and Sons Inc, 1987;803.
142. Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS: Co-expression of human cancer-associated epitopes on mucin molecules. *Int J Cancer*. 1987;39:68.
143. Bast RC Jr, Knapp RC: The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma. In: DeVita V, Hellman S and Rosenberg DA, eds. Important advances in oncology, Philadelphia, PA: Lippincott, 1987;39.
144. Bast RC Jr, Knapp RC: Humoral markers for epithelial ovarian carcinoma. In: Piver SM, ed. Ovarian malignancies diagnostic and therapeutic advances: London, Churchill Livingstone, 1987:11.
145. Zurawski VR Jr, Broderick SF, Pickens P, Knapp RC, Bast RC Jr: Serum CA 125 levels in a large group of nonhospitalized women: Relevance for the early detection of ovarian cancer. *Obstet Gynecol*. 1987;69:606.
146. Finkler NJ, Bast RC Jr, Knapp RC: Tumor markers in gynecologic cancer. *Contemporary OB/GYN*. Sept 1987:29.
147. Finkler NJ, Bast RC Jr, Knapp RC: Monoclonal antibodies in ovarian cancer. In: Kupchik, HZ ed. *In Vitro Diagnosis of Human Tumors Using Monoclonal Antibodies*, New York , NY: Marcel Dekker, Inc. 1988:141.
148. Zurawski VR Jr, Knapp RC: New prospects for diagnosis in ovarian cancer patients using the CA 125 immunoradiometric assay. In: CA 125 a new tool in the diagnosis and management of ovarian tumors. Ed. GB Massi. IL Sedicesimo, Firenze, 1987:109.
149. Bast RC Jr, Hunter V, Knapp RC: Pros and cons of gynecologic tumor markers. *Cancer*. 1987;60:1984.
150. Haisma HJ, Battaile A, Stradtman EW, Knapp RC, Zurawski VR Jr: Antibody-antigen complex formation following injection of labeled OC 125 monoclonal antibody into patients with ovarian cancer. *Int J Cancer*. 1987;40:758.
151. Niloff JM, Dubeshter B, Zurawski VR Jr, Gelman R, Hunt R, Bast RC Jr, Knapp RC: Survival following surgical reassessment in epithelial ovarian cancer. *Surgical Forum* 1987:470.
152. Finkler NJ, Kapnick SJ, Griffiths CT, Knapp RC: Elevated CA 125 serum levels and epithelial ovarian cancer metastatic to retroperitoneal lymph nodes. *Gynecol Oncol* 1988;29:356.

153. Knapp RC, Berkowitz RS, Leavitt T Jr, Bast RC Jr: Natural history and detection of ovarian cancer (revision). In Buschbaum H ed. Gynecology and obstetrics, Vol IV-Oncology, Hagerstown, Maryland: Harper and Row; 1988:1-15.
154. Boyer CM, Knapp RC, Bast RC Jr: Immunology and immunotherapy. In: Berek JS, Hacker NF (eds). Practical Gynecologic Oncology, Baltimore, MD: Williams and Wilkins. 1988:73-108.
155. Loeffler JS, Rosen EM, Niloff JM, Howes AE, Knapp RC: Whole abdominal irradiation for tumors of the uterine corpus. *Cancer* 1988;61:1332.
156. Haisma HJ, Moseley KR, Battaile AI, Griffiths TC, Zurawski VR, Knapp RC: Biodistribution, pharmacokinetics and imaging of ¹³¹I-labeled OC-125 in ovarian cancer. *Int J Cancer* 1988 Supplement 2:109.
157. Zurawski VR Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC Jr, Ritts RE Jr, Malkasian G: An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. *Gynecol Oncol* 1988;30:7.
158. Moseley KR, Knapp RC, Haisma HJ: An assay for the detection of human anti-murine immunoglobulins in the presence of CA 125 antigen. *J Immunol Methods* 1988;106:1.
159. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC: Comparison of serum CA 125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses. *Obstet Gynecol* 1988;72:659.
160. Zalutsky MR, Knapp RC, Bast RC Jr: Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. *Nucl Med Biol* 1988;15:431.
161. Malkasian GC, Knapp RC, Lavin PT, Zurawski VR, Podratz RC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE: Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. *Am J Obstet Gynecol.* 1988;159:341.
162. Haisma HJ, Moseley KR, Battaile A, Griffiths CT, Knapp RC: Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors. *Am J Obstet Gynecol.* 1988;159:843.
163. Moseley KR, Battaile A, Knapp RC, Haisma HJ: Localization of radiolabeled F(ab')₂ fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. *Int J Cancer.* 1988;42:368.

164. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC: Clear cell adenocarcinoma of the ovary; a clinical analysis and comparison with serous carcinoma. *Gynecol Oncol.* 1989;32:65.
165. Montag AG, Jenison EL, Griffiths T, Welch WR, Lavin PT, Knapp RC: Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. *Int J Gynecol Pathol.* 1989;8:85.
166. Band V, Hoffer AP, Band H, Rhinegardt AE, Knapp RC, Matlin SA, Anderson DJ. Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. *Gynec Oncol.* 1989;32:273.
167. Goodman HM, Buttlar CA, Niloff JM, Welch WR, Marck A, Feuer EJ, Lahman EA, Jenison EL, Knapp RC: Adenocarcinoma of the uterine cervix: Prognostic factors and patterns of recurrence. *Gynecol Oncol.* 1989;33:241.
168. Zurawski VR Jr, Davis HM, Finkler NJ, Harrison CL, Bast RC Jr, Knapp RC: Tissue distribution and characteristics of the CA 125 antigen. *Cancer Review* 1989;11:102.
169. Zurawski VR Jr, Davis HM, Finkler NJ, Harrison CL, Bast RC Jr, Knapp RC: Tissue distribution and characteristics of the CA 125 antigen. In: *Cancer Reviews*, Vols 11 & 12. Eds Hilgers J and Zotter SD, Editor in Chief, Olsson L , Copenhagen Denmark, Munksgaard Publishers, 1989;11-12:102.
170. Zalutsky MR, Bast RC Jr, Knapp RC: Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')₂ fragment in a xenograft model with circulating antigen. *Nucl Med Biol.* 1989;16:405.
171. Cramer DW, Willett WC, Bell DA, Ng WG, Harlow BL, Welch WR, Scully RE, Knapp RC: Galactose: Consumption and metabolism in relation to the risk of ovarian cancer. *Lancet* July 8, 1989:66.
172. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Anderson J: Predictive factors for long term survival in patients with advanced ovarian cancer. *Gynecol Oncol.* 1989;34:88.
173. Finkler NJ, Muto MG, Kassis AI, Weadock K, Tumeh SS, Zurawski VR Jr, Knapp RC: Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. *Gynecol Oncol.* 1989;34:339.
174. Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI: Influence of human anti-murine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. *AM J Obstet Gynecol.* 1989;161:1206.

175. Einhorn N, Knapp RC, Bast RC Jr, Zarawski VR Jr: CA 125 assay used in conjunction with CA 15-3 and TAG 72 assays for discrimination between malignant and nonmalignant diseases of the ovary. *Acta Oncologica* 1989;28:655.
176. Goodman HM, Niloff JM, Buttlar CA, Welch WR, Marck A, Feuer EJ, Lahman EA, Jenison E, Knapp RC: Adenocarcinoma of the cervical stump. *Gynecol Oncol* 1989;35:188.
177. Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr: CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. *Gynecol Oncol* 1990;36:161.
178. Sheets EE, Goodman HM, Knapp RC: The Cervix. In: Ryan KJ, Berkowitz R, Barbieri RL (eds). *Kistner's Gynecology*, 5th Edition, Chicago, IL: Year Book Medical Publishers, Inc. 1990:143.
179. Knapp RC, Lau CC: Monoclonal antibodies and radioimmunoconjugates: Keeping feasibility at center stage. In: *J Clin Oncol* 1990;8:1938.
180. Zurawski VR Jr, SjovalK, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, Ecklund G, Mattsson B, Connor RJ, Eng D, Prorok PC, Knapp RC, Einhorn N: Prospective evaluation of serum CA 125 levels in a normal population, Phase I: the specificities of single and serial determination in testing for ovarian cancer. *Gynecol Oncol* 1990;36:299.
181. Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC Jr: Antigenic heterogeneity in human ovarian cancer. *Gynecol Oncol* 1990;38:12.
182. Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp RC: Sonographic accuracy in the diagnosis of ovarian masses. *J Repro Med* 1990;35:491.
183. Muto M, Finkler N, Kassis A, Lepisto EM, Knapp RC: Human anti-murine antibody in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC 125. *Gynecol Oncol* 1990;38:244.
184. Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gull S, Knapp RC, Zurawski VR Jr, Schlom J, Kufe DW, Ritts RE Jr: Coordinate elevation of serum markers in ovarian cancer but not in benign clinical cancer. *Cancer* 1991;68:1758.
185. Brooks SE, Timmerman J, Lau CC, Tsao SW, Knapp RC, Sheets EE: Effect of differentiation agents on expression of CA 125, alkaline phosphatase and cytokeratins in human ovarian adenocarcinoma cells (OVCA 433). *Gynecol Oncol* 1991;42:265.
186. Tsao SW, Mok C, Oike K, Muto M, Goodman HM, Sheets EE, Berkowitz RS, Knapp RC, Lau CC: Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. *Anti Cancer Research* 1991;11:1975.

187. Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR Jr, Weadock K, Tumeh SS, Lavin P, Knapp RC: Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131 labeled monoclonal antibody OC 125. *Gynecol Oncol* 1992;45:265.
188. Mok Ch, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC: Unifocal origin of advanced human epithelial ovarian cancers. *Cancer Research* 1992;52:5119.
189. Einhorn N, Sjövall K, Knapp RC, Schoenfeld DA, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr: Prospective evaluation of serum CA 125 radioimmunoassay levels for early detection of ovarian cancer:. *Obstet Gynecol* 1992;80:14.
190. Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, Bell DA: Preoperative serum CA-125 levels in borderline tumors of the ovary. *Gynecol Oncol* 1992;46:226.
191. Gadick ES, Humm JL, Lau CC, Macklis RM, Bastert G, Knapp RC: Analysis of cytotoxicity of I-131-labeled OC 125 F(ab')₂ on human epithelial ovarian cancer cell lines. *Radiotherapy and Oncology* 1992;23:150.
192. Goodman HM, Harlow BL, Sheets EE, Muto MG, Brooks S, Steller M, Knapp RC, Berkowitz RS: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. *Gynecol Oncol* 1992; 46:367.
193. Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Muto MG, Welch WR, Goodman HM, Sheets EE, Berkowitz, RS, Lau CC: Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. *Gynecol Oncol*, 1993;48:5.
194. Barber HRK, Creasman WT, Knapp RC: A rational approach to ovarian masses. *Patient Care* 1993; 27:50.
195. Mok CH, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Berkowitz RS, Tsao SW : Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. *Cancer Research*, 1993; 53:1489.
196. Muto MG, Knapp RC: Serum CA 125 antigen in the early detection of ovarian cancer. In: *Early Detection of Ovarian Carcinoma with Transvaginal Sonography, Potentials and Limitations*. Ed: Fleischer AC, Assoc. Ed: Jones III HW, New York, Raven Press, 1993; 67-74.
197. Kim YB, Ehrmann RL, Dean B, Knapp RC, Lavin P, Niloff JM: Analysis of pap smear screening failure in patients presenting with cervical carcinoma. *The Cervix and the Lower Female Genital Tract*. 1993; 11:114.

198. Boyer CM, Knapp RC, Bast RC Jr: Biology and Immunology. In: Berek JS, Hacker NF (eds). Practical Gynecologic Oncology, 2nd Edition, Baltimore, MD: Williams and Wilkins. 1994;75-115.
199. Mok SC, Wong KK, Chan RKW, Lau CC, Tsao SW, Knapp RC, Berkowitz RS: Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. *Gynecol Oncol*, 1994; 52: 247
200. Knapp RC: Reflections on ovarian cancer: A 33-year experience. *Gynecol Oncol*, 1994; 54:124.
201. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TSK, Chew EC, Muto MG, Knapp RC, Berkowitz RS: Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). *Experimental Cell Research*. 1995; 218: 499.
202. Muto MG, Welch WR, Mok SC, Bandera CA, Fishbaugh PM, Tsao SW, Lau CC, Goodman HM, Knapp RC, Berkowitz RS: Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. *Cancer Research*, 1995; 5:49
203. Skates SJ, Xu Feng-J i, Yin-Hua Y, Sjovall K, Einhorn N, YuChiao C, Bast RC Jr, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. *Cancer*, 1995; 76:2004.
204. Knapp, RC, Jacobs I, Schwartz, P: Clinical perspectives on the use of the CA 125 Radioimmunoassay in ovarian cancer. *Contemporary Obstet & Gynecol*. 1996; 41:99.
205. Skates SJ, Knapp RC: Early detection of ovarian cancer with tumor markers as first-line test. *Current Problems in Obstet, Gynecol and Fertility*, 1996; 19:85.
206. Soto-Wright V, Skates S, Berkowitz RS, Bast RC Jr, Knapp RC. Natural history and detection of ovarian carcinoma (Revised edition). In Sciarra JJ ed. *Gynecology and Obstetrics, Vol-Oncology*, Philadelphia-New York: Lippincott-Raven. 1996; 1-12.
207. Hornstein MD, Goodman HM, Thomas PP, Knapp, RC, Harlow BL: Use of a second-generation CA 125 assay in gynecologic patients. *Gynecol Obstet Invest*, 1996;42:196.
208. Einhorn N, Bast R, Knapp R, Nilsson B. Sc., Zurawski V, Sjovall: Long-term follow-up of the Stockholm screening study on ovarian cancer. *Gynecol Oncol*. 2000; 79: 466.
209. Skates Sj, Menon IJ, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the risk of ovarian cancer from serial CA 125 values for preclinical detection in postmenopausal women. *J Clin Oncol*. 2003;

21(10 Suppl):206

210. Skates SJ, Triano R, Knapp RC: Longitudinal CA 125 Detection of sporadic papillary serous carcinoma of the peritoneum. *Int J Gynecol Cancer* 2003;13:693-696.
211. Chervenak FA, McCullough LB, Knapp RC, Caputo TA, Barber HRK: A clinically comprehensive ethical framework for offering & recommending treatment of cancer before and during pregnancy. *Cancer*. 2004; 100: 215.

Books:

1. Knapp RC, Berkowitz R, eds. *Gynecologic Oncology*. New York: Macmillan Co. 1986.
2. Knapp RC, Berkowitz R, eds. *Gynecologic Oncology*. 2nd Edition. New York: McGraw-Hill, Inc. 1993.

